Welcome to our dedicated page for Shoulder Innovations SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Shoulder Innovations, Inc. (NYSE: SI) provide detailed regulatory information about the company’s operations as a commercial-stage medical technology business focused on shoulder surgical care. These documents include current reports on Form 8-K that describe material events such as quarterly financial results and key corporate announcements.
Recent Forms 8-K furnished by Shoulder Innovations cover financial results for quarters ended June 30 and September 30, 2025. In these filings, the company provides net revenue, gross margin, operating loss, net loss and related financial data, along with discussions of factors affecting performance. The filings also reference non-GAAP measures such as Adjusted EBITDA and explain how these metrics are calculated and their limitations.
Other 8-K filings document significant corporate developments. For example, the company has furnished press releases announcing its initial public offering and convertible notes financing, as well as a strategic partnership with Interventional Systems to introduce a shoulder-specific micro-robotic solution that is expected to integrate with the ProVoyance platform. These filings help investors track how Shoulder Innovations is expanding its ecosystem of advanced implant systems, enabling technologies and instrument systems for shoulder arthroplasty.
On Stock Titan’s SEC filings page, users can access these reports as they are made available through the EDGAR system. AI-powered tools can assist in summarizing lengthy filings, highlighting items such as revenue trends, operating results, non-GAAP reconciliations and descriptions of material agreements or partnerships. Users can also review filing exhibits, including earnings press releases and, where provided, conference call transcripts furnished as exhibits to Form 8-K.
Together, the SEC filings for SI offer a structured view of Shoulder Innovations’ financial reporting, regulatory disclosures and significant events related to its focus on the shoulder surgical care market.
SHOULDER INNOVATIONS, INC. Chief Financial Officer Jeffrey S. Points increased his stake through option exercises and a share purchase. On March 13, 2026, he exercised stock options to acquire 13,264 shares of common stock at $2.4804 per share, converting a derivative position into stock. He also made an open-market purchase of 2,000 common shares at $15.00 per share the same day. Following these transactions, he holds 70,785 common shares directly and 50 shares indirectly held by his son. The exercised option was part of a grant that vests in 31 equal monthly increments beginning on March 31, 2025.
Shoulder Innovations director Paul Buckman exercised stock options to acquire 45,606 shares of Common Stock on March 13, 2026. He exercised 19,401 options at $2.4804 per share and 26,205 options at $2.0988 per share. To cover tax obligations, 7,006 shares were withheld in transactions priced at $14.62 and $14.82 per share. After these compensation-related transactions, Buckman directly holds 58,704 shares of Shoulder Innovations common stock.
Shoulder Innovations director Richard Buchholz reported an open-market purchase of 1,000 shares of common stock at $14.84 per share. This buy increased his direct ownership to 13,666 common shares. The transaction was classified as a standard open-market purchase, indicating he used personal capital to add to his position.
SHOULDER INNOVATIONS, INC. CEO & Executive Chairman Robert Joseph Ball bought 2,200 shares of Common Stock in an open-market transaction. The weighted average purchase price was $15.1782 per share, with individual trades ranging from $14.80 to $15.50. After this purchase, he directly owns 278,866 shares.
Shoulder Innovations, Inc. files its annual report describing a commercial-stage medical technology business focused solely on shoulder surgical care. The company sells advanced anatomic and reverse shoulder implant systems, its AI-enabled ProVoyance planning software, and a two-tray instrument platform designed to simplify procedures, especially in outpatient surgery centers.
Management estimates about 250,000 U.S. shoulder arthroplasty procedures in 2025, an approximately $1.7 billion market, and a global opportunity of about $2.7 billion growing roughly 11% annually through 2029. Its implants have been used in more than 17,500 procedures, with clinical studies showing long-term durability of the InSet Glenoid design.
The report highlights a specialized sales model targeting roughly 1,800 high-volume U.S. surgeons, strong adoption of ProVoyance in virtually all Shoulder Innovations cases, and a 50% increase in procedure volume from 2024 to 2025. As of March 3, 2026, the company had 20,647,526 common shares outstanding and continues to expand its product pipeline, including metal-sensitive implants, fracture and revision solutions, and a developing shoulder-specific robotics platform.
Shoulder Innovations reported strong growth but widening losses for the fourth quarter and full year 2025, and announced that director Michael Carusi will not stand for re-election at the 2026 annual meeting, a decision the company says is not due to any disagreement with management or the board.
Fourth quarter net revenue rose 65% to $14.4 million, while full-year net revenue increased 50% to $47.3 million, driven by higher implant system volumes and new customers. Gross margin remained high at about 77% for both the quarter and the year, reflecting attractive product economics.
Despite this growth, operating expenses climbed sharply, leading to a 2025 operating loss of $26.3 million and a net loss of $40.4 million. The company ended 2025 with $124.3 million in cash, cash equivalents and marketable securities, and issued 2026 net revenue guidance of $62 million to $65 million, implying growth of roughly 31% to 37% over 2025.
SHOULDER INNOVATIONS, INC. director Andrew Hykes filed an initial Form 3 to report his beneficial ownership as a company insider. The filing lists him as a director and does not show any share purchases, sales, or other transactions in this excerpt.
Shoulder Innovations, Inc. reported that on February 26, 2026, Geoff Pardo resigned as a Class I director, a member of the Compensation Committee, and Chair of the Nominating and Corporate Governance Committee, effective immediately. The company stated his resignation was not due to any disagreement with management or the Board.
On the same date, the Board appointed Andrew (Drew) Hykes, age 53, as a Class I director and member of the Compensation Committee, also effective immediately. He will receive standard non-employee director compensation and enter into the company’s standard indemnification agreement. The Board determined he is an independent director and meets New York Stock Exchange and Exchange Act requirements for Compensation Committee service.
The filing and accompanying press release highlight Mr. Hykes’s more than 25 years of medical device and healthcare experience, including leadership roles at Okami Medical, Inari Medical, Sequent Medical, and Medtronic, as well as his banking background and business degrees from the University of Wisconsin–Madison and Harvard Business School.
Shoulder Innovations, Inc. CEO and Executive Chairman Robert Joseph Ball reported exercising stock options for common stock on February 6, 2026. He acquired 10,000 shares at $2.4804 per share and 2,062 shares at $2.0988 per share through option exercises coded “M.”
After these transactions, Ball directly beneficially owned 276,666 shares of common stock. His option holdings included 319,756 and 181,376 stock options remaining after the exercises. Footnotes note that his holdings include over 140,000 shares previously received without consideration as in‑kind distributions from several investment funds.
Shoulder Innovations, Inc. granted Chief Financial Officer Jeffrey S. Points a stock option on January 30, 2026. The option covers 126,357 shares of common stock at an exercise price of $14.16 per share.
The option is held directly and vests in four equal annual installments, with one-fourth of the underlying shares vesting on March 1 each year, beginning March 1, 2027. After this grant, Points beneficially owns 126,357 stock options tied to common shares.